Major Depressive Disorder Market Report and Forecast 2025-2034

Major Depressive Disorder Market Outlook

The major depressive disorder market size was valued at USD 6.1 billion in 2024, driven by the rising prevalence of major depressive disorder across the 8 major markets. The market is expected to grow at a CAGR of 5.3% during the forecast period of 2025-2034, with the values likely to rise from USD 6.4 billion in 2025 to USD 9.6 billion by 2034. 

Major Depressive Disorder Market Overview

Major depressive disorder (MDD) is characterized by persistently low and depressed mood along with a loss of interest in everyday activities. The incidence rate is rising in the younger population due to alcohol and drug abuse. According to the Mental Health America prevalence data of 2023, 16.39% of youth aged between 12-17 years suffered from at least one major depressive episode (MDE) in the previous year. The state prevalence of MDE in youth was reported to be 12.57% in New Jersey and 21.13% in Oregon.

Major depressive disorder is highly prevalent in women, owing to several factors such as hormonal differences, different psychosocial stressors, and childbirth effects. The average onset of this psychiatric disorder is estimated to be 40 years . The rising prevalence of mental illnesses is projected to boost the major depressive disorder market growth in the forecast period.

The market is witnessing steady growth supported by the surge in drug approvals by the health regulatory agencies. For instance, in October 2023, the United States Food and Drug Administration (FDA) approved gepirone ER, marketed as Exxua, to treat major depressive disorder (MDD). The medication developed by Fabre-Kramer Pharmaceuticals, Inc. (a United States pharmaceutical company) targets the serotonin 1A receptor, a key mood regulator. Exxua is the only drug that selectively stimulates the receptor without any adverse symptoms of weight gain or sexual dysfunction. The availability of such drugs in the market will positively influence the market landscape.

The major depressive disorder market demand is further bolstered by the rising geriatric population at a higher risk of developing mental disorders. The rising mental health campaigns and initiatives by the government to support patients suffering from clinical depression are also anticipated to accelerate the market growth in the forecast period.

Major Depressive Disorder Market Trends

Major Depressive Disorder Market Segmentation

Market Breakup by Product Type

• Benzodiazepines

• Antidepressant Drugs

• SSRIs

• SNRIs

• Others

The market for treating major depressive disorder (MDD) can be segmented by product type, including benzodiazepines, antidepressant drugs, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and other medications. This market segment comprises the pharmacological options available for managing MDD.

Market Breakup by Treatment Type

• Medication
  • Antidepressant Drugs
  • Adjunctive Therapies

• Psychotherapy
  • Cognitive Behavioral Therapy (CBT)
  • Interpersonal Therapy (IPT)
  • Other Therapeutic Approaches

• Brain Stimulation Therapies
  • Electroconvulsive Therapy (ECT)
  • Transcranial Magnetic Stimulation (TMS)

The major depressive disorder market report includes segmentation based on treatment types. It includes medication, psychotherapy, and brain stimulation therapies. Under medication, options include antidepressant drugs and adjunctive therapies. Psychotherapy includes cognitive behavioral therapy (CBT), interpersonal therapy (IPT), and other therapeutic approaches. Brain stimulation therapies consist of electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS). This market segment offers a range of interventions available for managing MDD, aligning with patients’ needs and preferences.

Market Breakup by Diagnosis Tests

• Psychological Assessments

• Blood Tests

• Imaging Technologies

• Laboratory Tests

• Other Diagnostic Tools

Based on diagnostic tests, the major depressive disorder market share includes psychological assessments, blood tests, imaging technologies, laboratory tests, and other diagnostic tools. This market segment shows the approaches to diagnosing MDD, which forms an essential part of effective treatment planning.

Market Breakup by Distribution Channel

• Pharmacies and Retail Stores

• Online Pharmacies

• Hospitals and Clinics

• Others

Distribution channels in the market include pharmacies and retail stores, online pharmacies, hospitals and clinics, and other channels. The diverse network of these channels helps in accommodating the diverse clinical needs of patients suffering from major depressive disorder.

Market Breakup by End User

• Hospitals and Clinics

• Mental Health Centres

• Ambulatory Surgical Centres (ASCs)

Major end users of the major depressive disorder market are hospitals and clinics, mental health centers, and ambulatory surgical centers (ASCs). Mental health centers provide mental health care, such as diagnosis and therapy to MDD patients.

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

• China

Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and China. North America dominates the regional market, attributed to the high prevalence rates of major depressive disorder. Rapid technological advancements in the healthcare sector and the rise in the geriatric population base, which is more susceptible to develop the condition. Such factors are expected to further bolster the market growth in the region.

Major Depressive Disorder Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Lundbeck

• AbbVie

• Relmada Therapeutics

• Axsome Therapeutics

• Alkermes

• Intra-Cellular Therapies

• Allergan plc

• Pfizer Inc.

• Sanofi S.A.

• Johnson & Johnson

• Merck & Co.

• Eli Lilly and Company

• Takeda Pharmaceutical Company Limited

• AstraZeneca Plc

• GSK plc

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

Key Queries Solved in the Major Depressive Disorder Market Report

• How has the major depressive disorder market performed so far and how is it anticipated to perform in the coming years?
• What are the major market trends influencing the market? 
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• How does the prevalence and incidence of major depressive disorder affect the market landscape?
• How does the rise in the geriatric population impact the major depressive disorder market size?
• What treatment type of major depressive disorder will dominate the market share? 
• Which diagnostic method is expected to have a high market value in the coming years?
• Which product type will experience the highest demand in the market segment?
• How will the ongoing clinical trials impact the market value during the forecast period? 
• What are the factors driving regional disparities in major depressive disorder treatment and outcomes?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?